Key facts
- It has raised $2.7M; the latest was PE Growth/Expansion in Jan 2025.
- Notable investors include Business Finland, Nordic Mentor Network For Entrepreneurship, Excedea Capital, Health Incubator Helsinki, SPARK Finland.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Sartar Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Sartar Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Sartar Therapeutics
Developer of a soft tissue sarcoma therapy intended to treat the unmet medical needs of patients suffering from cancer. The company exploits principles of precision medicine, drug repurposing and reformulation, and the repositioning of anagrelide, enabling patients receiving cancer therapies to access novel therapeutic options.
- Sector
- Healthcare
- HQ
- Helsinki, Finland
- Founded
- 2016
- Employees
- 5
- Website
- sartartherapeutics.com/
- Ownership
- Privately Held (backing)
Sartar Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sartar Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sartar Therapeutics in its N-PORT filings yet. We sweep new filings monthly.